EASD 2018—Insulin degludec/liraglutide superior to insulin glargine for T2D control as supplement to SGLT2i


  • Robert Davies and Harry O'Connor
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Insulin degludec/liraglutide (IDegLira) plus a sodium-glucose cotransporter 2 inhibitor (SGLT2i) is more effective than insulin glargine (IGlar U100) plus SGLT2i for glycemic control, body weight, and total daily insulin dose.

Why this matters

  • There is a need for treatment intensification when treating progressive type 2 diabetes mellitus (T2DM).

 Study design

  • 26-week, phase 3b, open-label, randomized trial.
  • 420 patients with T2D were randomly assigned 1:1 to either IDegLira plus SGLT2i or IGlar U100.
  • HbA1c, body weight, insulin dose, and number of hypoglycemia (HG) episodes were analyzed.
  • Funded by: Novo Nordisk A/S.

Key results

  • Significant reduction of HbA1c from baseline to week 26 for IDegLira compared with IGlar U100 (8.2%-6.3% vs 8.4%-6.7%; P<.0001>
  • IDegLira group observed an unchanged mean body weight, while a 2.0 kg mean weight gain was seen in the IGlar U100 group (P<.0002>
  • 58% lower HG rate with IDegLira vs IGlarU100 (P=.0035).
  • Total daily insulin dose was 36U for IDegLira vs 54U for IGlarU100 (P<.0001>

Limitations

  • No cost analysis of IDegLira.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit